Quick Answer
Cyclerion Therapeutics, Inc. reported Net Income Loss of -$3.53 million for the year ending 2025.
- Cyclerion Therapeutics, Inc. showed a decrease of -15.4% in Net Income Loss from 2024 to 2025.
- This data is from Cyclerion Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$25.28 million | Q2 2018: -$29.78 million | Q3 2018: -$29.29 million | Q1 2019: -$37.38 million | Q2 2019: -$32.25 million | Q3 2019: -$27.32 million | Q1 2020: -$20.23 million | Q2 2020: -$19.53 million | Q3 2020: -$18.81 million | Q1 2021: -$6.95 million | Q2 2021: -$16.18 million | Q3 2021: -$11.29 million | Q1 2022: -$12.98 million | Q2 2022: -$13.39 million | Q3 2022: -$10.50 million | Q1 2023: -$6.95 million | Q2 2023: -$4.18 million | Q3 2023: $7.57 million | Q1 2024: -$1.54 million | Q2 2024: -$1.32 million | Q3 2024: -$723.0 thousand | Q1 2025: -$1.43 million | Q2 2025: -$324.0 thousand | Q3 2025: -$976.0 thousand.
- Over the full 8 years of available data (2018 to 2025), Cyclerion Therapeutics, Inc.'s Net Income Loss has grown by 96.9%.
- Historical annual values: Fiscal year 2025: -$3.53 million | Fiscal year 2024: -$3.06 million | Fiscal year 2023: -$5.26 million | Fiscal year 2022: -$44.08 million | Fiscal year 2021: -$51.65 million | Fiscal year 2020: -$77.80 million | Fiscal year 2019: -$123.01 million | Fiscal year 2018: -$115.25 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: